Tsfg LLC increased its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 144.1% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 1,440 shares of the biotechnology company’s stock after acquiring an additional 850 shares during the quarter. Tsfg LLC’s holdings in Sarepta Therapeutics were worth $107,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds have also bought and sold shares of SRPT. Nuveen Asset Management LLC lifted its holdings in Sarepta Therapeutics by 8.1% during the fourth quarter. Nuveen Asset Management LLC now owns 473,401 shares of the biotechnology company’s stock valued at $80,710,000 after purchasing an additional 35,549 shares in the last quarter. Sei Investments Co. lifted its holdings in Sarepta Therapeutics by 1.7% during the third quarter. Sei Investments Co. now owns 52,433 shares of the biotechnology company’s stock valued at $7,363,000 after purchasing an additional 894 shares in the last quarter. BLB&B Advisors LLC purchased a new position in Sarepta Therapeutics during the fourth quarter valued at approximately $511,000. Exchange Traded Concepts LLC purchased a new position in Sarepta Therapeutics during the fourth quarter valued at approximately $90,000. Finally, Nia Impact Advisors LLC purchased a new position in Sarepta Therapeutics during the fourth quarter valued at approximately $1,643,000. 89.69% of the stock is currently owned by institutional investors.
In related news, Director Hans Lennart Rudolf Wigzell sold 10,000 shares of the company’s stock in a transaction dated Monday, March 8th. The shares were sold at an average price of $83.51, for a total value of $835,100.00. Following the completion of the sale, the director now directly owns 26,518 shares of the company’s stock, valued at $2,214,518.18. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director M Kathleen Behrens sold 5,000 shares of the company’s stock in a transaction dated Wednesday, March 10th. The stock was sold at an average price of $85.76, for a total transaction of $428,800.00. Following the completion of the sale, the director now directly owns 135,517 shares of the company’s stock, valued at $11,621,937.92. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company’s stock.
NASDAQ SRPT opened at $72.63 on Friday. The company’s 50-day moving average price is $79.89 and its 200-day moving average price is $117.82. The company has a current ratio of 6.14, a quick ratio of 5.56 and a debt-to-equity ratio of 0.79. The stock has a market cap of $5.77 billion, a PE ratio of -9.29 and a beta of 2.01. Sarepta Therapeutics, Inc. has a 12 month low of $68.04 and a 12 month high of $181.83.
Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Monday, March 1st. The biotechnology company reported ($2.40) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.99) by ($0.41). The company had revenue of $145.10 million during the quarter, compared to the consensus estimate of $145.54 million. Sarepta Therapeutics had a negative return on equity of 61.62% and a negative net margin of 121.30%. The company’s revenue for the quarter was up 45.0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($3.16) earnings per share. As a group, sell-side analysts forecast that Sarepta Therapeutics, Inc. will post -8.2 earnings per share for the current year.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities approaches for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.
Recommended Story: Asset Allocation Models, Which is Right For You?
Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics, Inc. (NASDAQ:SRPT).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.